4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma
Public ClinicalTrials.gov record NCT00818454. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter Randomized Study Starting With a 4 Week 2 Way Crossover Double Blind Treatment Phase Comparing the Efficacy and Safety of Combivent CFC MDI to Albuterol HFA MDI Followed by a 4 Week Open Label Combivent Respimat Treatment Phase When All Study Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma (GINA 2007 Treatment Steps 3-5)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary goal of this trial is to compare the efficacy and safety of COMBIVENT CFC MDI with albuterol HFA MDI, the current standard reliever medication in asthma. In the first cross-over part of the study (Treatment Phases 1 and 2) the marketed product, COMBIVENT CFC MDI will be used. In the second, parallel group part of the trial (Treatment Phase 3) COMBIVENT RESPIMAT will be tested for acute bronchodilator efficacy in a blinded manner at the clinic visits. During the third 4-week treatment phase open label COMBIVENT RESPIMAT will be used for symptom relief as needed.
Study identification
- NCT ID
- NCT00818454
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 226 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2008 (Type not available)
- Primary completion
- Sep 2009 (Actual)
- Completion
- Not listed
- Last update posted
- Feb 14, 2014
Started 2008
United States locations
- U.S. sites
- 41
- U.S. states
- 23
- U.S. cities
- 39
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1012.57.121 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 1012.57.144 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1012.57.145 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1012.57.124 Boehringer Ingelheim Investigational Site | Palmdale | California | — | — |
| 1012.57.137 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 1012.57.130 Boehringer Ingelheim Investigational Site | Stockton | California | — | — |
| 1012.57.134 Boehringer Ingelheim Investigational Site | Centennial | Colorado | — | — |
| 1012.57.151 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 1012.57.119 Boehringer Ingelheim Investigational Site | Panama City | Florida | — | — |
| 1012.57.149 Boehringer Ingelheim Investigational Site | Winter Park | Florida | — | — |
| 1012.57.104 Boehringer Ingelheim Investigational Site | Augusta | Georgia | — | — |
| 1012.57.107 Boehringer Ingelheim Investigational Site | Coeur d'Alene | Idaho | — | — |
| 1012.57.127 Boehringer Ingelheim Investigational Site | Normal | Illinois | — | — |
| 1012.57.140 Boehringer Ingelheim Investigational Site | Louisville | Kentucky | — | — |
| 1012.57.143 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 1012.57.126 Boehringer Ingelheim Investigational Site | North Dartmouth | Massachusetts | — | — |
| 1012.57.147 Boehringer Ingelheim Investigational Site | North Dartmouth | Massachusetts | — | — |
| 1012.57.113 Boehringer Ingelheim Investigational Site | Minneapolis | Minnesota | — | — |
| 1012.57.131 Boehringer Ingelheim Investigational Site | Plymouth | Minnesota | — | — |
| 1012.57.116 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1012.57.146 Boehringer Ingelheim Investigational Site | Bozeman | Montana | — | — |
| 1012.57.132 Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| 1012.57.139 Boehringer Ingelheim Investigational Site | Skillman | New Jersey | — | — |
| 1012.57.109 Boehringer Ingelheim Investigational Site | Chapel Hill | North Carolina | — | — |
| 1012.57.118 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 1012.57.128 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 1012.57.102 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1012.57.129 Boehringer Ingelheim Investigational Site | Lake Oswego | Oregon | — | — |
| 1012.57.138 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 1012.57.108 Boehringer Ingelheim Investigational Site | Hershey | Pennsylvania | — | — |
| 1012.57.114 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1012.57.111 Boehringer Ingelheim Investigational Site | Upland | Pennsylvania | — | — |
| 1012.57.142 Boehringer Ingelheim Investigational Site | Easley | South Carolina | — | — |
| 1012.57.117 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1012.57.103 Boehringer Ingelheim Investigational Site | Union | South Carolina | — | — |
| 1012.57.136 Boehringer Ingelheim Investigational Site | El Paso | Texas | — | — |
| 1012.57.148 Boehringer Ingelheim Investigational Site | Killeen | Texas | — | — |
| 1012.57.101 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1012.57.141 Boehringer Ingelheim Investigational Site | Seattle | Washington | — | — |
| 1012.57.150 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
| 1012.57.105 Boehringer Ingelheim Investigational Site | Madison | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00818454, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 14, 2014 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00818454 live on ClinicalTrials.gov.